钠-葡萄糖协同转运蛋白2抑制剂对急性心力衰竭住院患者临床结局的影响  

Effect of sodium-glucose cotransporter 2 inhibitors on clinical outcome in hospitalized patients with acute heart failure

作　　者：刘双双[1] 杨丽娜[1] 李影[1] 佟菲 王传合[1] 韩苏[1] 孙兆青[1] 孙志军[1] Liu Shuangshuang;Yang Lina;Li Ying;Tong Fei;Wang Chuanhe;Han Su;Sun Zhaoqing;Sun Zhijun(Department of Cardiology,Shengjing Hospital of China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院心内科,沈阳110004

出　　处：《中华心力衰竭和心肌病杂志（中英文）》2022年第2期166-169,共4页Chinese Journal of Heart Failure and Cardiomyopathy

摘　　要：新型降糖药物钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)在心力衰竭(HF)治疗领域成功跨界,作为慢性HF“新四联”治疗的新成员,获国内外多项HF指南推荐。但在急性HF(AHF)住院患者中启动SGLT2i的疗效性及安全性循证数据有限。随着近期EMPULSE研究结果的公布,SGLT2i在AHF患者中的临床获益得到了进一步证实。Sodium-glucose cotransporter 2 inhibitors(SGLT2i),a novel glucose-lowering drug,become the"crossover star"for the treatment of heart failure(HF).As a new member of the new quadruple therapy in chronic HF,SGLT2i has been recommended by many international and national guidelines for HF management.However,the initiation of SGLT2i in hospitalized patients with acute HF(AHF)is uncertain and has limited data.The clinical benefits of SGLT2i in patients with AHF have been further confirmed recently with the publication of the EMPULSE study results.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 急性心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]